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In Brief
Nucleophosmin mutations are the most
common genetic change in adult
leukemia. Nichol et al. show that in
leukemia resistant to the differentiating
effects of retinoic acid, nucleophosmin
functions as a non-canonical
transcriptional co-repressor by recruiting
the chromatin remodeler BRG1.
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Perturbation in the transcriptional control of genes
driving differentiation is an established paradigm
whereby oncogenic fusion proteins promote leuke-
mia. From a retinoic acid (RA)-sensitive acute pro-
myelocytic leukemia (APL) cell line, we derived an
RA-resistant clone characterized by a block in tran-
scription initiation, despite maintaining wild-type
PML/RARA expression. We uncovered an aber-
rant interaction among PML/RARA, nucleophosmin
(NPM), and topoisomerase II beta (TOP2B). Sur-
prisingly, RA stimulation in these cells results in
enhanced chromatin association of the nucleosome
remodeler BRG1. Inhibition of NPM or TOP2B abro-
gated BRG1 recruitment. Furthermore, NPM inhibi-
tion and targeting BRG1 restored differentiation
when combined with RA. Here, we demonstrate a
role for NPM and BRG1 in obstructing RA differenti-
ation and implicate chromatin remodeling in medi-
ating therapeutic resistance in malignancies. NPM
mutations are the most common genetic change in
patients with acute leukemia (AML); therefore, our
model may be applicable to other more common
leukemias driven by NPM.INTRODUCTION
Nuclear receptors are ligand-activated transcription factors that
transduce messages carried by signaling molecules into tran-
scriptional responses. The retinoid receptor alpha (RARA) finely
tunes granulocytic differentiation by acting as a transcriptional
regulator of genes involved in this program (Kastner et al.,
2001).
In the absence of ligand, RARA is bound to DNA along with its
partner receptor, the retinoid X receptor (RXR), and co-repres-
sors (Heinzel et al., 1997; Ho¨rlein et al., 1995; Kurokawa et al.,2938 Cell Reports 14, 2938–2949, March 29, 2016 ª2016 The Author
This is an open access article under the CC BY license (http://creative1995). Upon binding ligand, RARA undergoes a conformational
change, releasing co-repressors, and recruiting an arsenal of
co-activator proteins that facilitate the recruitment of RNA poly-
merase II (RNAPII) and the general transcription factors (GTFs) to
the promoter (Dilworth and Chambon, 2001; Shao et al., 2000).
Several chromatin-remodeling complexes make direct physical
interactions with RARA and carry out structural modifications
of chromatin to regulate transcription. BRG1, the ATPase sub-
unit of the SWI/SNF complex, plays a critical role in differentia-
tion through regulation of gene expression and is required for
transactivation by many nuclear receptors, including RARA (Dil-
worth et al., 2000).
The importance of RARA in granulopoiesis is evident in acute
promyelocytic leukemia (APL). APL is a form of acute myeloid
leukemia (AML) characterized clinically by an accumulation of
immature promyelocytes in the bone marrow and peripheral
blood, stemming from a blockage in myeloid differentiation
(Collins et al., 1990; Melnick and Licht, 1999). The majority of
APL patients respond to the differentiating action of pharmaco-
logical concentrations of all-trans retinoic acid (RA), a vitamin A
derivative. In fact, this treatment was the first example of a suc-
cessful therapeutic approach inducing differentiation rather than
cytotoxicity, and it has since become the prototype for differen-
tiation therapy in cancer. Although treatment with RA alone re-
sults in a complete remission, a significant proportion of patients
relapse and subsequently develop RA resistance, a phenome-
non that can be modeled in vitro (Gallagher, 2002; Rosenauer
et al., 1996).
At themolecular level, APLblasts harbor a chromosomal trans-
location involving the RARA gene located on chromosome 17
(Melnick and Licht, 1999; Rowley et al., 1977). Numerous fusion
partners of RARA have been identified, but the PML gene of
chromosome 15 is the most common translocation site. Approx-
imately 95% of affected individuals have the (15;17) transloca-
tion, producing the PML/RARA chimera (Jurcic et al., 2007).
PML/RARA acts as a dominant-negative inhibitor of retinoid
receptor function. The fusion protein still binds DNA, heterodi-
merizes with RXR, and binds RA (Benedetti et al., 1997; Dong
et al., 1996; Jansen et al., 1995; Perez et al., 1993). However,
PML/RARA is a much more potent repressor than RARA, as its
commons.org/licenses/by/4.0/).
Figure 1. NPM Interacts with PML/RARA
and TOP2B in the MR2 Resistant Cells Only
(A) Differential protein (top) and mRNA (bottom)
levels of six proteins identified as being differen-
tially associated with a GST-PML/RARA fusion in
MR2 cells versus NB4 cells.
(B) GST pull-down assay defines PML/RARA
domains that mediate interaction with NPM. The
purified GST, GST-PML, GST-RARA, and GST-
PML/RARA proteins were incubated with nuclear
extracts from NB4 and MR2 cells.
(C) Endogenous coIP with TOP2B and NPM
antibodies followed by immunoblotting indicates
an interaction between NPM and TOP2B solely in
MR2 cells.is unresponsive to physiological concentrations of ligand, such
that co-repressors are not released and RA target genes remain
unexpressed (Grignani et al., 1998; He et al., 1998; Lin et al.,
1998).
APL cell lines are a useful model to study the conversion of
transcription factors into oncogenic facilitators in other hemato-
logical malignancies. Additionally, in vitro-derived RA-resistant
cells provide clues into the mechanisms of RA resistance in
APL. We have isolated three RA-resistant clones from the
parental RA-sensitive cell line NB4, denoted MR2, MR4, and
MR6 (Rosenauer et al., 1996).
We previously reported that RA-resistance in theMR2 cell line,
which retains wild-type PML/RARA, is associated with an altered
pattern of high-molecular weight complexes binding to PML/
RARA (Rosenauer et al., 1996). We furthered this observation
by identifying eight members of these complexes. These include
nucleophosmin (NPM), a nucleolar protein (Prestayko et al.,Cell Rep1974) intimately linked with the develop-
ment of AML (Falini et al., 2005), and
another was topoisomerase II beta
(TOP2B), whichwe characterized as play-
ing a central role in RA-resistance (McNa-
mara et al., 2008). NPM plays important
roles in the regulation of cell proliferation
and apoptosis and is more highly ex-
pressed in malignant and proliferating
cells than in normal cells (Chan et al.,
1989; Feuerstein and Mond, 1987).
Conversely, NPM expression is downre-
gulated in cells undergoing differentiation
(Hsu and Yung, 1998, 2003). Strikingly,
NPM1 is commonly mutated in leukemic
blasts in a high proportion of patients
with AML, with the most common muta-
tions leading to aberrant cytoplasmic
translocation of this nucleolar phospho-
protein (termed NPMc+). However, it
remains unclear how cells harboring
elevated NPM achieve malignant proper-
ties. Here, we characterize the role of
NPM as a transcriptional co-repressor of
the PML/RARA oncoprotein and a keymediator of the differentiation block observed in RA-resistant
APL cells.
RESULTS
Levels of PML/RARA-Interacting Proteins Are Elevated
in the MR2 Resistant Line
Previous work using high-performance liquid chromatography
(HPLC) analysis of PML/RARA in the RA-resistant MR2 line re-
vealed the formation of higher molecular-weight PML/RARA
complexes, not evident in the parental NB4 line (Rosenauer
et al., 1996). Using mass spectrometry, we identified eight mem-
bers of these complexes with increased interaction with PML/
RARA in MR2, compared to NB4 (Table S1). Examination of
the expression profile of six of these reveals a strong upregu-
lation at the protein level in the MR2 versus the NB4, without
a corresponding robust increase in mRNA (Figure 1A). Thisorts 14, 2938–2949, March 29, 2016 2939
upregulation is selective, as several other known nuclear recep-
tor co-regulators have the same, or even decreased, expression,
in MR2 (Figure S1A).
We examined in more detail the upregulation of NPM levels,
given this protein’s central role in a large proportion of adult
leukemia (Falini et al., 2005).
Despite higher levels of NPM protein in the MR2 line, expres-
sion of Nucleolin (NCL), another major nucleolar protein overex-
pressed in rapidly dividing cells, remained the same between
NB4 and MR2 (Figure S1B). The differences in NPM levels be-
tween the two cell lines are not due to differences in the solubility
of NPM (Figure S1C). Furthermore, our resistantMR2 cells do not
have the NPMc+mutation, as direct sequencing ofNPM by tradi-
tional Sanger sequencing revealed no differences in the NPM1
sequence (data not shown), and NPM is located exclusively
within the nucleus, with no evidence of cytoplasmic NPM (Fig-
ures S1D and S1E). Finally, an RNA sequencing (RNA-seq)-
based transcriptome analysis of both cell lines confirmed the
minimal difference in NPM transcript levels and showed no dif-
ferences in promoter, terminator, or exon usage that would
account for the dramatic increase in NPM protein levels (Fig-
ure S1F). However, we also called variants from our RNA-seq
data to identify genomic differences between our two cell lines
(Table S2). There are three variants in the NPM1 gene (one in
the 50 UTR and two intronic) in the MR2 cell line, which might
be involved in the enhanced translation of NPM.
NPM Interacts with PML/RARA Only in the Resistant
Cell Line
We confirmed our mass spectrometry results by performing a
glutathione S-transferase (GST) pull-down with untreated NB4
and MR2 nuclear extracts (Figure 1B). An association between
NPM and PML/RARA is detectable in MR2 only, and this interac-
tion is mediated through the PML moiety of the fusion.
We previously validated TOP2B as another aberrantly associ-
ated PML/RARA protein in the MR2 line (McNamara et al., 2008).
We therefore used endogenous co-immunoprecipitation (coIP;
Figure 1C) to show that NPM and TOP2B also associate. Consis-
tent with the previous results, pull-down with a TOP2B antibody
results in pull down of NPM from MR2 cellular extracts only.
NPM Localizes to the CEBPB Gene Locus in MR2 Cells
The PML/RARA fusion protein blocks myeloid differentiation by
repressing RA-mediated gene expression and neutrophil matu-
ration. Quantitative real-time PCR analyses over an 8 hr RA treat-
ment reveal induction of four RARA target genes in NB4 cells,
while the same accumulation is not observed in the RA-resistant
cell line, MR2 (Figures 2A and S2A).
There are two well established RA-target genes, CEBPbeta
(CEBPB) (Duprez et al., 2003) and CEBPepsilon (CEBPE) (Chih
et al., 1997), that both play a critical role in the differentiation of
the myeloid lineage. The mRNA levels of these genes correlate
with their respective protein levels, as assessed by western
blotting (Figure 2B).
Normal transcriptional regulation in response to RA requires
the coordinated action of RARA and a variety of cofactor com-
plexes (Bastien and Rochette-Egly, 2004). In order to study the
exact steps of transcriptional activation in the presence of the2940 Cell Reports 14, 2938–2949, March 29, 2016PML/RARA fusion and at which step a transcriptional blockade
occurs in the resistant cells, we performed high-resolution
quantitative chromatin immunoprecipitation (ChIP) analysis.
This assay enables us to generate detailed maps of protein oc-
cupancy on the CEBPB locus after stimulating the transactiva-
tion process. Figure 2C shows the most relevant features of
this gene including the location of seven amplicons used for
quantitative real-time PCR quantification of the ChIP-enriched
DNA. Both NB4 andMR2 express similar levels of the fusion pro-
tein, and initial ChIP profiling of the CEBPB locus under basal
conditions shows similar recruitment levels and patterns of local-
ization for RARA in both cell lines (Figure 2D). However, a
dramatically enhanced association of NPM is observed exclu-
sively in the resistant cells (Figure 2E).
Differential RNAPII Patterning and Pre-initiation
Complex Recruitment between Sensitive and Resistant
Cells at CEBPB in the RA-Activated State
RNAPII activity can be stimulated at various stages of transcrip-
tion by the action of myriad regulators of recruitment and post-
recruitment steps. CEBPB shows little preloaded RNAPII in
both the sensitive and resistant cells (Figure 3A). Upon transcrip-
tional activation with RA, the total amount of RNAPII associated
with the proximal promoter increases in NB4 cells, but not in
MR2 cells (Figure 3A). This suggests that RA activates this
gene, at least in part, by promoting RNAPII recruitment.
RNAPII phosphorylation of the serine 5 and 2 residues (S5P
and S2P) of the carboxy-terminal domain (CTD) repeats occurs
at post-recruitment steps and is catalyzed by protein kinases
in the initiation and elongation complexes, respectively (Sims
et al., 2004). In the sensitive cells, S5P and S2P patterning on
both CEBPB and CEBPE increases strongly upon activation.
S5P, a mark of active transcription initiation, is increased upon
treatment at the 50 end of the gene. S2P, a mark of actively elon-
gating RNAPII, increases toward the 30 end of the gene (Figures
3B, 3C, and S2B–S2D). In contrast, neither of these signals
increases in response to RA treatment in the resistant cells.
The failure of MR2 cells to recruit and activate RNAPII in
response to RA stimulation led us to examine the recruitment
of subunits of the pre-initiation complex (PIC). MR2 cells fail to
recruit CDK7 (Figure 3D), the kinase subunit of the general tran-
scription TFIIH, a key component of the PIC, and which is also
the principal S5 kinase (Hengartner et al., 1998). Recruitment
of additional components of the PIC, such as TFIIB and TFIIF,
is also stimulated by RA in NB4, but not in MR2 (Figures 3E
and S2E). Upon activation by ligand, RARA interacts with and
recruits the Mediator co-activator complex, which stimulates
RNAPII activity by diverse mechanisms, including positive ef-
fects on PIC formation, enhancer-promoter chromatin looping,
and transcription elongation. The subunit of the Mediator com-
plex that is responsible for this interaction is MED1 (Yuan
et al., 1998). We have shown that MED1 interacts with the
PML/RARA found in NB4 in a ligand-dependent manner (Shao
et al., 2000). Furthermore, the MR2 cell line maintained normal
MED1 complexes that interacted with retinoid receptors in a
ligand-dependent manner, when assessed by GST pull-down
assay. However, by conducting ChIP tiling analyses, we now
show that RA fails to recruit MED1 to the endogenous CEBPB
Figure 2. Defective Transcriptional Activation of RARA Target Genes upon RA Treatment in MR2 Correlates with Increased NPM at the
Promoter
(A) Quantitative real-time PCR analysis of CEBPB and CEBPEmRNA induction following 8 hr RA treatment expressed as fold induction over untreated cells after
normalization to 18S rRNA levels. The error bars represent the SEM.
(B) Immunoblot analysis demonstrating differential CEBPB and CEBPE protein expression in response to RA treatment.
(C) Schematic of the CEBPB locus indicating the overall gene structure. The amplicons used in real-time PCR quantification of ChIP-enriched DNA are named
according to their relative distance (bps) to the transcription start site.
(D) High-density ChIP tiling of RARA at theCEBPB locus under basal conditions in NB4 andMR2 cells and immunoblot analysis of PML/RARA expression levels in
the two cell lines.
(E) High-density ChIP tiling of NPM at the CEBPB locus under basal conditions in NB4 and MR2 cells.promoter in MR2 (Figure 3F). Together, these data demonstrate
that themolecular mechanism of RA resistance involves a defect
in RNAPII recruitment and activation at the promoter of key dif-
ferentiation genes.
Modulation of NPM Levels Mediates Sensitivity to RA-
Induced Gene Transcription and Differentiation
To examine whether NPM overexpression and aberrant interac-
tion with PML/RARA is responsible for the repression of RA-
induced gene expression in MR2, we treated both NB4 and
MR2 with the NPM inhibitor NSC348884, which has been shown
to disrupt NPM’s higher order structures (Qi et al., 2008). Strik-
ingly, in the resistant cells, NPM inhibition, in combination with
RA, leads to increases in CDK7 recruitment (Figure 4A), S5 phos-phorylation (Figure 4B), and restored mRNA expression of the
RA-target genes (Figures 4C, left, S3A, and S3B).
The above data led to the hypothesis that this inhibition might
also abolish the differentiation block in the MR2 line. Treatment
of sensitive cells with RA induces expression of the myeloid-
specific cell surface marker, cd11c. We first assessed cd11c
expression by fluorescence-activated cell sorting (FACS) anal-
ysis in NB4 and MR2 cells treated for 3 days either with RA,
NPM inhibitor (NPMi), or the combination (Figures 4C, middle,
and S3C, top). We observed that RA alone and the combination
of RA and NPMi are both sufficient to cause increased cd11c cell
surface expression in NB4. However, in MR2, only the combina-
tion treatment led to the reestablishment of this differentiation
marker.Cell Reports 14, 2938–2949, March 29, 2016 2941
Figure 3. Differential Recruitment of Transcription Initiating Factors to CEBPB in Response to RA Treatment
(A) High-density ChIP tiling of RNAPII at CEBPB before and after RA treatment (1 hr) of NB4 and MR2 cells.
(B) ChIP tiling of RNAPII phosphorylation on serine 2 (S2P) at CEBPB before and after RA treatment (1 hr) of NB4 and MR2 cells.
(C) ChIP tiling of RNAPII phosphorylation on serine 5 (S5P) at CEBPB before and after RA treatment (1 hr) of NB4 and MR2 cells.
(D) ChIP tiling of CDK7 at CEBPB before and after RA treatment (1 hr) of NB4 and MR2 cells.
(E) ChIP tiling of TFIIB at CEBPB before and after RA treatment (1 hr) of NB4 and MR2 cells.
(F) ChIP tiling of MED1 at CEBPB before and after RA treatment (1 hr) of NB4 and MR2 cells.To confirm that NPMi overcomes the differentiation block in
APL cells, we performed a nitro-blue-tetrazolium (NBT) reduction
analysis, which assesses terminal granulocytic differentiation2942 Cell Reports 14, 2938–2949, March 29, 2016(Klein et al., 1998). While NPMi alone had little discernible effect
on differentiation in either cell line, RA and NPMi co-treatment
leads to significant NBT reduction within 5 days (Figures 4C,
Figure 4. Inhibition of NPMRestoresMyeloid LineageDifferentiation in Resistant Cells andOverexpression of NPM Impairs Differentiation in
Sensitive Cells
(A) ChIP analysis was carried out using protein extracts of DMSO, RA (1 hr), NPMi (16 hr) or NPMi and RA-treated (16 hr + 1 hr) MR2, and NB4 cells using an
antibody recognizing CDK7.
(B) ChIP analysis was carried out using protein extracts of DMSO, RA (1 hr), NPMi (16 hr) or NPMi and RA-treated (16 hr + 1 hr) MR2, and NB4 cells using
antibodies against RNAPII S5P.
(C) Quantitative real-time PCR analysis of CEBPBmRNA induction following DMSO, RA, NPMi or RA, and NPMi treatment of MR2 cells. The data are expressed
as fold induction over DMSO treated cells and normalized to 18S ribosomal RNA levels. The error bars represent the SE (left). The percentages of MR2 cells
(legend continued on next page)
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right, and S3C, bottom). This is consistent with the ChIP anal-
ysis, mRNA expression, and cd11c data, where only a modest
response to treatment was observed in the MR2 cell line in
response to 106 M RA.
In agreement with these data, the converse experiment,
whereby overexpression of NPM is induced in the RA-sensitive
line, led to RA-resistance. Figure 4D confirms overexpression
of NPM. We first examined whether NPM overexpression would
affect mRNA expression of RA target genes. Compared to
the empty vector control, the NPM-overexpressing clone has
reduced CEBPB, CEBPE, ICAM1, and CDKN1A mRNA induc-
tion (Figures 4D, left, and S3D). This translates to a robust
decrease in NBT reduction compared to that of the NB4 control
(Figure 4D, right). Cumulatively, these results support evidence
that increased expression of NPM is necessary and sufficient
for the inhibition of RA-induced gene expression and differentia-
tion in an APL cell line.
RA Induces Recruitment of the Chromatin Remodeler
BRG1 to CEBPB in a TOP2B/NPM-Dependent Fashion
In order to activate gene expression, RARsmust override repres-
sive chromatin structures. To this end, ligand-induced confor-
mational changes in the receptors will cause the dissociation
of co-repressors and the concomitant recruitment of co-activa-
tors necessary for RNAPII recruitment (Chen et al., 1999). In the
resistant and sensitive cells, there is an increase in histone H4
acetylation (Figure 5A) throughout the gene body, as well as in
the promoter in response to RA. This indicates that activator-
induced histone acetylation is not sufficient for RNAPII activa-
tion, an observation also made in other systems (Galbraith
et al., 2013).
Surprisingly, ChIP tiling upstream of transcription initiation re-
vealed a more robust recruitment of the chromatin-remodeler
ATPase subunit BRG1 to the CEBPB locus in response to RA-
treatment in the resistant cells compared to the sensitive cells
(Figure 5B). Examination of theBRG1expressionprofile discloses
a strong upregulation of BRG1 protein in MR2 cells compared to
NB4 cells (Figure 5C, bottom), without a corresponding biologi-
cally significant increase in mRNA (Figure 5C, top).
Having shown that TOP2B interacts with both PML/RARA and
NPM in the resistant cells, we next used endogenous coIP (Fig-
ure 5D, left) to investigate whether BRG1 and TOP2B associate.
Pull-down with TOP2B followed by immunoblotting for BRG1
reveals a basal interaction between the two proteins that is
enhanced with RA treatment (Figures 5D, right, and S4A). In
agreement with the ChIP analysis, this interaction is limited to
the resistant line. To examine whether this interaction is neces-
sary for the aberrant recruitment of BRG1 to the CEBPB locus
in MR2, we treated both lines with the TOP2B inhibitor, ICRF,
which induces TOP2B degradation (Xiao et al., 2003). ChIP ana-expressing the differentiation marker cd11c in response to 3-day exposure to
reduction assay performed on MR2 cells treated with RA, NPMi, or the combina
(D) NB4 cells were stably transfected with empty vector (NB4 EV) or the NPM
separating total nuclear proteins via SDS-PAGE, followed by western blotting usin
induction following 8 hr RA treatment expressed as fold induction over DMSO
represent the SEM (left). The NBT reduction results in response to 5-day expo
performed in triplicate. The error bars represent SEM (right).
2944 Cell Reports 14, 2938–2949, March 29, 2016lyses performed on cells treated with RA, ICRF, or the combina-
tion (Figure 5E, top) demonstrated a direct correlation between
TOP2B inhibition and reduced BRG1 recruitment in the MR2
cell line. Interestingly, treatment with ICRF in NB4 cells enhanced
BRG1 recruitment, suggesting a differential functional outcome
of BRG1 recruitment between the cell lines (Figure S4B, top).
Similar results were obtained when both lines were treated
with the NPMi alone or in combination with RA (Figures 5E, bot-
tom, and S4B, bottom). Treatment with ICRF for 24 hr was suf-
ficient to degrade TOP2B, but had no discernible effect on
NPM levels, nor were levels of HNRNPU, another member iden-
tified in our mass spectrometry screen, affected (Figures S4C
and S4D). Together, these results indicate that the resistant
cell line expressed elevated levels of BRG1 and that recruitment
of BRG1 to the promoter of RA-target genes was dependent on
the repressive factors TOP2B and NPM in MR2 cells only. These
data suggest NPM, TOP2B, and BRG1 cooperate as a repres-
sive complex, effectively suppressing PML/RARA-mediated
transcription.
BRG1 Knockdown Restores Sensitivity to RA
We next investigated whether BRG1 functioned as a repressor
of RA-induced transcriptional activation in the MR2 cell line.
There were five stable BRG1 knockdown clones, along with
a stable clone expressing a non-targeting short hairpin RNA
(shRNA), that were created in both the NB4 and MR2 lines.
Based on the efficacy of BRG1 knockdown in MR2 (Figure
S5A), we selected three clones (sh2, sh3, and sh5) for further
analysis.
Quantitative real-time PCR analysis of RA-target gene expres-
sion revealed BRG1 knockdown restored sensitivity to RA treat-
ment in the MR2 cell line, in all three clones tested (Figures 5F,
top, S5B, and S5C). We assessed cd11c expression by FACS
analysis in NB4 and MR2 clones treated for 3 days with RA (Fig-
ure S5D). RA alone and the combination of RA and BRG1 knock-
down were both sufficient to cause increased cd11c cell surface
expression in the RA-sensitive NB4 cells. However, in the MR2
clones, only the combination of RA with knock down of BRG1
led to the reestablishment of this differentiation marker.
To confirm that BRG1 knockdown overcomes the differentia-
tion block in APL cells, we again performed an NBT reduction
analysis. While BRG1 knockdown alone had little effect on dif-
ferentiation of any of the cell lines, RA treatment after BRG1
knockdown lead to significant NBT reduction within 5 days
(Figures 5F, bottom, and S5E). This is consistent with the
mRNA expression and cd11c data, where only a modest
response to treatment was observed in the MR2 cell line in
response to 106 M RA. Cumulatively, these results indicate
that knock down of BRG1 in resistant cells restored sensitivity
to RA-mediated differentiation, from early gene expression toRA, NPMi, or a combination of both are shown (middle). The results of NBT
tion for 5 days are shown (right).
expression plasmid (NB4 NPM). The overexpression of NPM was verified by
g NPMantibody (middle). Quantitative real-time PCR analysis ofCEBPBmRNA
treated cells after normalization to 18S rRNA levels is shown. The error bars
sure to RA are shown. The results are representative of three experiments
Figure 5. Targeting BRG1 Restores Sensitivity to RA-Induced Gene Transcription and Differentiation
(A) High-density ChIP tiling of acetylated H4 (AcH4) at the CEBP locus before and after RA treatment (1 hr) of NB4 and MR2 cells.
(B) High-density ChIP tiling of BRG1 at the CEBPB locus before and after RA treatment (1 hr) of NB4 and MR2 cells.
(C) Immunoblot analysis demonstrating differential basal BRG1 protein expression in NB4 andMR2 cells (bottom) with no corresponding increase in BRG1mRNA
levels (top). SMARCA4 is the gene that encodes for the protein known as BRG1.
(D) Endogenous coIP with TOP2B antibody followed by immunoblotting for BRG1 and TOP2B indicates an interaction between BRG1 and TOP2B solely in MR2
cells (left). The densitometry values of immunoprecipitated BRG1 were normalized to the amount of immunoprecipitated TOP2B and reported as fold induction
over DMSO treated NB4 cells. The densitometry analyses were performed with ImageJ software (right).
(legend continued on next page)
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terminal functional capacity. Moreover, these results substanti-
ate the hypothesis that BRG1 acts as a transcriptional repressor
in the MR2 cell line.
DISCUSSION
We observed that PML/RARA associated with a higher molecu-
lar weight complex in MR2 cells than NB4 cells. Subsequent
mass spectrometry identified eight proteins that had previously
undescribed interactions with PML/RARA. We found that two
of these, TOP2B and NPM, mediate repression in MR2, as inhi-
bition of these proteins resulted in a loss of resistance to RA. We
thus hypothesize the existence of a co-repressor complex in
MR2 that interacts with PML/RARA and represses genes critical
for cellular differentiation. We support this by demonstrating that
both TOP2B andNPMare necessary for the recruitment of BRG1
and that functional inhibition of these proteins abates BRG1’s
presence at CEBPB in MR2 cells. Similarly, many of the other
proteins identified in the MR2 PML/RARA complex (Table S1)
have been shown to interact with BRG1. For example, SAP130
associates with the co-repressor complex mSin3A, which incor-
porates BRG1 under certain conditions (Fleischer et al., 2003).
HNRNPU has been shown to form a complex with BRG1 that
is necessary for RNAPII mediated transcriptional activity and in-
teractions between HNRNPC1/C2 and the SWI/SNF complex,
which includes BRG1, have also been reported (Mahajan et al.,
2005; Vizlin-Hodzic et al., 2011). Most interestingly, PML itself
has been shown tomediate recruitment of BRG1 to theOct4 pro-
moter (Chuang et al., 2011).
Our data define a function for NPM as a negative regulator of
RA-induced gene regulation and differentiation toward granulo-
cytes. In RA-resistant cells, we show an interaction between
PML/RARA, the fusion most commonly underlying APL, and
NPM that is mediated through the PML portion of the chimera.
The presence of NPM is inversely correlated with PIC formation
at the CEBPB locus, and pharmacological targeting of NPM in
combination with RA relieved the inhibition of transcription
exerted by this protein.
NPM is irrefutably linked to human tumorigenesis. Disruption
of the NPM gene by translocation is found in human hematopoi-
etic malignancies, and NPM appears to contribute to oncogen-
esis by activating the oncogenic potential of the fused protein
partner (Bischof et al., 1997; Fujimoto et al., 1996). Moreover,
NPM acts as a transcriptional co-repressor during RA-induced
differentiation of HL60 cells (Liu et al., 2007). NPM enhances
the proliferative potential of hematopoietic stem cells, and
NPM overexpression increases HSC survival upon DNA damage
and oxidative stress (Li et al., 2006). Variant calling from our
RNA-seq data identified three variants in the NPM1 gene in
the MR2 cell line. These data are especially intriguing given the
recent report of two AML patients with NPM mutations in the(E) High-density ChIP tiling of BRG1 at CEBPB after treatment with DMSO, RA
(overnight pretreatment) and RA (1 hr) in MR2 cells (top). The high-density ChIP t
(overnight), or a combined treatment of NPMi (overnight pretreatment) and RA (1
(F) Quantitative real-time PCR analysis ofCEBPBmRNA induction in BRG1MR2-k
untreated cells after normalization to 18S rRNA levels. The error bars represent th
MR2 cells treated with RA for 5 days, with retreatment at day 3 (bottom), are sho
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esting findings highlight the importance of untranslated regions
in NPM expression in leukemia.
The RNA-seq variant calling also revealed a putative mutation
in the ligand binding domain in PML/RARA in the MR2 cell line.
However, we have several lines of evidence that lead us to
believe that this variant is not a significant contributor to RA-re-
sistance. First, the genomic sequence of PML/RARA in MR2
is not altered. Our group has previously published a character-
ization of three RA-resistant subclones, including this MR2
clone, derived from NB4 (Shao et al., 1997). As we reported,
these three resistant clones were subjected at that time to
DNA sequencing. Sequencing revealed a point mutation in the
PML/RARA sequence of only one of the three subclones, MR4.
To confirm this finding, we recently re-sequenced the region sur-
rounding the identified variant with Sanger sequencing and veri-
fied that the sequence in MR2 is indeed wild-type (Figure S1G).
Second, the 3H-t[RA] HPLC profiles (Rosenauer et al., 1996)
showed no peak at a high a higher molecular weight in MR4,
the clone with the genomic alteration in PML/RARA sequence,
indicating that RA binding to PML/RARA does not occur in this
clone. In contrast, the MR2 clone not only shows a high molec-
ular weight peak, this peak is higher than what corresponds to
PML/RARA in NB4. This interesting piece of data, showing that
RA binds to an aberrant PML/RARA complex inMR2, is the start-
ing point for our studies to identify the members of that complex
and how those impact RA resistance. Finally, if the mutation in
the LBD of the PML/RARA in MR2 cells affected the functionality
of the PML/RARA, we would hypothesize that even after
removing all the other barriers to the RA response (such as
TOP2B, NPM, and BRG1), we would see no transactivation in
response to RA. As is shown in this manuscript and our previous
publication (McNamara and Miller, 2008), this is clearly not the
case. Inhibition of TOP2B, NPM, or BRG1 enables the RA trans-
activation function of the PML/RARA in the MR2 cell line, as
clearly demonstrated by ChIP assays, RA-target gene mRNA
levels and ultimately, cellular differentiation.
Transcriptional profiling by ChIP analysis surprisingly revealed
that RA treatment of our resistant cells was associated with
enhanced recruitment of BRG1. BRG1 is an ATPase helicase
subunit of the SWI/SNF family of proteins that serves to regulate
gene expression by altering the chromatin landscape surround-
ing genes (Wilson and Roberts, 2011). Thus, BRG1 can function
both to activate and repress gene expression (Murphy et al.,
1999). We hypothesized that transcriptional repression by
BRG1 mediates resistance to RA-induced differentiation in
MR2. Abrogation of BRG1 activity restored sensitivity to RA as
observed by early gene expression, cd11c surface expression,
and functional capacity of differentiated cells.
BRG1 as a transcriptional repressor has been demonstrated
in other contexts. For example, Ooi et al. showed that BRG1(1 hr), the TOP2B inhibitor ICRF (overnight), or a combined treatment of ICRF
iling of BRG1 at the CEBPB locus after treatment with DMSO, RA (1 hr), NPMi
hr) in MR2 cells (bottom) are shown.
nockdown clones following 8 hr RA treatment expressed as fold induction over
e SE (top). The results of NBT reduction assay performed on BRG1 knockdown
wn.
enhanced REST-mediated repression by recruiting and stabiliz-
ing binding of this repressor complex to chromatin (Ooi et al.,
2006). BRG1 also interacts with and recruits DNA methyltrans-
ferases, thus promoting gene silencing by DNA methylation
(Datta et al., 2005). Additionally, BRG1 interacts with co-repres-
sive complexes such as mSin3A/HDAC2/PRMT5, which pro-
mote histone tail deacetylation and methylation and subsequent
chromatin condensation (Pal et al., 2003). Our results are
congruent with the above findings and provide a setting in which
BRG1 serves as a mediator of transcriptional repression. How-
ever, whether or not this is dependent upon its nucleosomal
repositioning capacity remains a topic of current investigation.
Based on the data presented herein, we hypothesize that
BRG1 might act to further contribute to a more heterochromatic
architecture at the promoters of RA target genes in the MR2
cell line.
Cellular mechanisms underlying resistance to chemothera-
peutic agents have been carefully studied, as experimental
models can be easily generated via in vitro selection. Resistance
to the differentiating effects of RA in APL cells in vitro and in vivo
is traditionally associated with a mutation in the ligand-binding
domain of the PML/RARA oncogenic fusion protein (Shao
et al., 1997). In contrast, we report that stable resistance to RA
in an acute leukemia cell line, in the context of a wild-type
PML/RARA, is driven by an aberrant association with a putative
co-repressor complex containing NPM and TOP2B, leading to
recruitment of BRG1 to RA-target genes.
In summary, while the challenge of overcoming the maturation
block in APL resistant cells has been met in vitro, it will be impor-
tant to determine the relevance of our findings to other forms of
leukemia. Additionally, while RA is validated as an effective front-
line strategy in APL, our understanding of the molecular under-
pinnings of APL pathology and the response to RA remains
tenuous. Elucidation of these may shed light onto common etiol-
ogies for other AML subtypes, particularly those with NPMmuta-
tions and fusions, and lead to the development of therapeutic
strategies for the less curable forms of this disease.
EXPERIMENTAL PROCEDURES
Materials
RPMI 1640 and fetal bovine serum were purchased from Wisent. All-trans RA
and the nucleophosmin inhibitor, NSC 348884, were purchased from Sigma-
Aldrich and Axon Medchem BV, respectively. The TOP2B inhibitor ICRF-193
was obtained from Biomol.
Cell Culture
The RA-resistant cell line MR2 was derived from the parental APL cell line NB4
(Rosenauer et al., 1996). All cell lines were maintained in RPMI 1640 supple-
mented with 10% fetal bovine serum and penicillin/streptomycin (Wisent).
RNA Extraction and Analysis
mRNA was isolated using the Absolutely RNA Miniprep Kit (Agilent Technolo-
gies) and cDNA was generated from 1 mg total RNA using the iScript cDNA
Synthesis Kit (Bio-Rad Laboratories). We determined relative mRNA levels,
normalized to endogenous 18S rRNA (TaqMan hs99999901_s1 probe, Applied
Biosystems), using SYBR Green I chemistry in an ABI 7500 Fast Real-Time
PCR machine (Applied Biosystems). Table S3 shows primer sequences.
Western Blotting
See Supplemental Information.ChIP
ChIP analyses were performed as detailed in Gomes et al. (2006); for details,
see Supplemental Information.
CoIP
Approximately 73 106 cells were harvested and lysed in IP lysis buffer (20 mM
Tris-HCL pH 7.5, 420 mM NaCl, 2 mM MgCl2, 10% Glycerol, 0.5% Glycerol,
0.5% NP-40, and 0.5% Triton-X) completed with protease inhibitors. There
was 2 mg of protein per condition, diluted in 0.5% Tritron-X IP buffer, that
were pre-cleared for 2 hr with protein G sepharose, after which the beads
were removed. TOP2B or IgG antibody was added overnight at 4C. Immune
complexes were recovered with protein G sepharose, washed three times in
0.5% Triton-X IP buffer, once in 0.1% Triton-X IP buffer, then boiled in 2X
SDS sample buffer, and subsequently analyzed by western blot.
Stable NPM Transfectants
Transfection of lentiviral constructs encodingNPM1-HA and thePuro-HA-empty
vector control (Applied Biological Materials) was performed using Lipofectamine
2000 (Carlsbad) with Opti-MEM media (Invitrogen). Plasmids were co-trans-
fected with three lentivirus packaging constructs, PLP1, VSVG, and PLP2, into
293FT cells. At 48 hr post-transfection, the virus supernatant was collected,
centrifuged, and filtered through a 0.45 mm filter. There were two million cells
that were transduced by centrifugation at 800 g for 30 min and maintained for
48 hr at 37C with 5% CO2 before beginning selection with puromycin.
shRNA-Mediated Knockdown
Cell lines stably transducedwith shRNAs targeting BRG1were established us-
ing a 24 hr polybrene (5 mg/ml) transduction of NB4 and MR2 cells with
Mission TRC lentiviral particles (Sigma-Aldrich). Approximately 1 3 106 cells
were infected with 200,000 lentiviral units in 2 ml of complete RPMI 1640
media. At day 5 post-transduction, the cells were given fresh media supple-
mented with 1 mg/ml puromycin (Invitrogen) for selection purposes.
Differentiation Assays
Cell surface expression of cd11c (BD Biosciences) was determined by flow-
assisted cell sorting according to the antibody manufacturer’s specifications
using the FACSCalibur flow cytometer. Background staining was controlled
using an isotype control PE-conjugated mouse IgG1 kappa (BD Biosciences).
For each sample, viable cells were gated and expression of cd11c surface
markers of 13 104 cells was evaluated. NBT reduction assays were performed
as described (Momparler et al., 1990). The fraction of NBT-positive (blue) cells
was determined by counting using a hemocytometer.
Statistical Analyses
All results are an average of three independent experiments. Error bars repre-
sent the SEM determined using GraphPad Prism software. The results of the
ChIP experiments in Figures 4, S4, and 5 are the average of at least two inde-
pendent PCRs from two separate immunoprecipitations from two independent
cell cultures.
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